Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dosage of immunotherapy and other treatments, to clarify the relationship between EGFR mutation, immune microenvironment and the efficacy of immunotherapy. In this review, we summarized the newly updated data about immunotherapy in EGFR mutant NSCLC in term of pre-clinical study, programmed cell death protein ligand 1 (PD-L1) expression, tumor mutation burden and treatment. .
【中文题目：EGFR突变非小细胞肺癌免疫治疗 相关研究进展】 【中文摘要：靶向治疗和免疫治疗是非小细胞肺癌（non-small cell lung cancer, NSCLC）重要治疗手段。目前表皮生长因子受体（epidermal growth factor receptor, EGFR）突变NSCLC临床和基础研究还处在探索阶段，需要优化免疫治疗与其他治疗方式的疗效、组合、顺序和剂量，明确EGFR突变与免疫微环境、免疫治疗疗效三者间的关系。本文就免疫治疗EGFR突变NSCLC临床前研究、程序性死亡受体1（programmed cell death protein ligand 1, PD-L1）表达和肿瘤突变负荷、治疗等方面最新研究进行综述。 】 【中文关键词：肺肿瘤；表皮生长因子受体；免疫治疗】.
Keywords: Epidermal growth factor receptor; Immunotherapy; Lung neoplasms.